Philip Morris International to Acquire Vectura Group

Molex to Acquire Vectura Group From Philip Morris International (PMI)

September 17, 2024

Medical Devices

Vectura Group Ltd., a subsidiary of Philip Morris International (PMI) and part of Vectura Fertin Pharma, has signed an agreement to be sold to Molex Asia Holdings Ltd. The deal includes upfront cash consideration of GBP 150 million (subject to customary adjustments) plus potential deferred payments of up to GBP 148 million, with closing subject to regulatory approvals and other customary conditions.

Japan Tobacco Group Acquires Vector Group Ltd for $2.4 Billion

August 21, 2024

Consumer Products

Japan Tobacco Inc. (JT Group) agreed to acquire Vector Group Ltd. in an all-cash tender offer and second-step merger at $15.00 per share, valuing the transaction at approximately $2.4 billion. The acquisition completed on October 7, 2024, after the tender offer and statutory merger, and Vector Group became a wholly owned subsidiary of JT Group.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

Philip Morris Holland Holdings Acquires Swedish Match in Recommended Cash Offer

November 10, 2022

Consumer Products

Philip Morris Holland Holdings B.V. (PMHH), an affiliate of Philip Morris International (PMI), launched a recommended cash offer to acquire all shares of Swedish Match AB at SEK 106 per share. After regulatory approvals and tendering to meet deal conditions, PMHH declared the offer unconditional and began completing the acquisition, targeting delisting and compulsory redemption of remaining shares.

Philip Morris International Acquires Fertin Pharma from EQT Private Equity

July 1, 2021

Pharmaceuticals

Philip Morris International has agreed to acquire Fertin Pharma, a Denmark-headquartered specialist CDMO in oral and intra-oral delivery technologies, from EQT Private Equity for a headline enterprise value of DKK 5.1 billion. Fertin Pharma — which operates sites in Denmark, Canada and India and employs more than 860 people — will strengthen PMI's smoke-free and beyond-nicotine product capabilities; the transaction is subject to customary approvals.

H.I.G. Capital Acquires BioVectra Inc.

November 4, 2019

Pharmaceuticals

H.I.G. Capital, through an affiliate, completed the acquisition of BioVectra Inc., a Canadian contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), intermediates and biologics. The deal — a carve-out from Mallinckrodt — positions H.I.G. to support BioVectra's growth and further expand its manufacturing capabilities across Charlottetown, Prince Edward Island and Windsor, Nova Scotia.